C&EN3d
Silybin A
1. CAS Reg. No. 142797-34-0. 2. CAS Reg. No. 65666-07-1. 3. CAS Reg. No. 36804-18-9. BAY 2666605 1 is a phosphodiesterase 3 (PDE3) inhibitor that is being developed to combat melanoma. It is active ...
Need to financially support Indian cities for development of infrastructure: GITAM Vice-Chancellor
Supporting Indian cities' infrastructure development is crucial for economic growth, public amenities, and sustainable urban planning, emphasized by experts.
Verona Pharma: Great Year For Share Price, But Competition Threatens Bull Thesis
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Cystic Fibrosis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the safety, and tolerability and efficacy ...
pharmaphorum3d
Verona cues up filings for COPD drug after it aces phase 3 test
Ensifentrine is billed as a first-in-class dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4), and is thought to combine bronchodilator and anti-inflammatory properties in one ...
labiotech21d
Eight respiratory disease companies advancing innovative therapies in 2025
Ensifentrine, which is now being sold under the brand name Ohtuvayre, is a dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. This dual inhibition enables the ...